SCHEMBL3531189

SCHEMBL3531189

O=C(NC1CCN(c2ccnc(-c3ccccc3C(F)F)n2)CC1)C1CCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
OPRD1 P41143 1/20 0.41
RET P07949 2/20 0.41
DRD2 P14416 2/20 0.41
HTR2A P28223 2/20 0.41
DRD3 P35462 2/20 0.41
NPC1 O15118 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
RAB9A P51151 3/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
MAP4K4 O95819 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
USP30 Q70CQ3 1/20 0.38
ACKR3 P25106 1/20 0.38
TSHR P16473 1/20 0.37
KRAS P01116 1/20 0.37
SOS1 Q07889 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991417 1.00 KDM4E (0.41) KDM4EHTTOPRD1RETDRD2
SCHEMBL12991386 0.88 ALDH1A1 (0.51) KDM4EHTTOPRD1RETDRD2
SCHEMBL3534311 0.88 ALDH1A1 (0.51) KDM4EHTTOPRD1RETDRD2
SCHEMBL12991606 0.87 KDM4E (0.44) KDM4EHTTOPRD1RETDRD2
SCHEMBL3534380 0.87 KDM4E (0.44) KDM4EHTTOPRD1RETDRD2
SCHEMBL13769346 0.79 KDM4E (0.40) KDM4ERETNPC1SMN1; SMN2RAB9A
SCHEMBL4014748 0.79 KDM4E (0.40) KDM4ERETNPC1SMN1; SMN2RAB9A
SCHEMBL13157344 0.79 KDM4E (0.40) KDM4ERETNPC1SMN1; SMN2RAB9A
SCHEMBL3534191 0.78 DRD2 (0.41) KDM4EDRD2HTR2AALDH1A1TSHR
SCHEMBL3529715 0.71 CYP1A2 (0.66) KDM4EHTTALDH1A1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 KDM4E 2470/4885HTT 1077/4885OPRD1 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.